CN103725703B - 用于制备包装机器的方法以及包装机器 - Google Patents

用于制备包装机器的方法以及包装机器 Download PDF

Info

Publication number
CN103725703B
CN103725703B CN201410005350.7A CN201410005350A CN103725703B CN 103725703 B CN103725703 B CN 103725703B CN 201410005350 A CN201410005350 A CN 201410005350A CN 103725703 B CN103725703 B CN 103725703B
Authority
CN
China
Prior art keywords
dna
head
packaging
phage
heads
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201410005350.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103725703A (zh
Inventor
维尼加拉·绕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Catholic University of America
Original Assignee
Catholic University of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catholic University of America filed Critical Catholic University of America
Publication of CN103725703A publication Critical patent/CN103725703A/zh
Application granted granted Critical
Publication of CN103725703B publication Critical patent/CN103725703B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10141—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10151—Methods of production or purification of viral material
    • C12N2795/10152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN201410005350.7A 2010-04-09 2011-04-08 用于制备包装机器的方法以及包装机器 Active CN103725703B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32233410P 2010-04-09 2010-04-09
US61/322,334 2010-04-09
US13/082,466 US8802418B2 (en) 2010-04-09 2011-04-08 Protein and nucleic acid delivery vehicles, components and mechanisms thereof
CN201180030396.9A CN103003431B (zh) 2010-04-09 2011-04-08 蛋白质与核酸递送媒介物、其组成部分及它们的机理
US13/082,466 2011-04-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180030396.9A Division CN103003431B (zh) 2010-04-09 2011-04-08 蛋白质与核酸递送媒介物、其组成部分及它们的机理

Publications (2)

Publication Number Publication Date
CN103725703A CN103725703A (zh) 2014-04-16
CN103725703B true CN103725703B (zh) 2016-02-10

Family

ID=44761088

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201410005350.7A Active CN103725703B (zh) 2010-04-09 2011-04-08 用于制备包装机器的方法以及包装机器
CN201180030396.9A Active CN103003431B (zh) 2010-04-09 2011-04-08 蛋白质与核酸递送媒介物、其组成部分及它们的机理

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201180030396.9A Active CN103003431B (zh) 2010-04-09 2011-04-08 蛋白质与核酸递送媒介物、其组成部分及它们的机理

Country Status (5)

Country Link
US (3) US8802418B2 (https=)
EP (2) EP2703491B1 (https=)
JP (2) JP5863766B2 (https=)
CN (2) CN103725703B (https=)
WO (1) WO2011125054A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2560045A1 (en) * 2003-12-17 2005-06-30 The Catholic University Of America Methods and compositions comprising bacteriophage nanoparticles
US9163262B2 (en) * 2003-12-17 2015-10-20 The Catholic University Of America In vitro and in vivo delivery of genes and proteins using the bacteriophage T4 DNA packaging machine
US20120214867A1 (en) * 2011-02-18 2012-08-23 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Bacteriophage T4 Nanoparticles for Eukaryotic Delivery
US9765122B2 (en) 2013-01-18 2017-09-19 University Of Washington Through Its Center For Commercialization Theragnostic particles
US9328149B2 (en) 2013-07-12 2016-05-03 The Catholic University Of America Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines
SG11201600853UA (en) 2013-08-05 2016-03-30 Twist Bioscience Corp De novo synthesized gene libraries
WO2016115522A2 (en) * 2015-01-16 2016-07-21 University Of Kentucky Research Foundation Lipid bilayer-integrated spp1 connector protein nanopore and spp1 connector protein variants for use as lipid bilayer-integrated nanopore
US10669304B2 (en) 2015-02-04 2020-06-02 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
EP3350314A4 (en) 2015-09-18 2019-02-06 Twist Bioscience Corporation OLIGONUCLEIC ACID VARIANT LIBRARIES VARIANT AND SYNTHESIS THEREOF
KR102794025B1 (ko) 2015-09-22 2025-04-09 트위스트 바이오사이언스 코포레이션 핵산 합성을 위한 가요성 기판
US20180112234A9 (en) 2016-03-14 2018-04-26 Intellia Therapeutics, Inc. Methods and compositions for gene editing
WO2017165859A1 (en) * 2016-03-24 2017-09-28 Research Institute At Nationwide Children's Hospital Modified viral capsid proteins
US10417457B2 (en) 2016-09-21 2019-09-17 Twist Bioscience Corporation Nucleic acid based data storage
EP4556433A3 (en) 2017-02-22 2025-08-06 Twist Bioscience Corporation Nucleic acid based data storage
CN106939355A (zh) * 2017-03-01 2017-07-11 苏州系统医学研究所 一种流感病毒弱毒活疫苗毒株的筛选和鉴定方法
CN108949701A (zh) * 2017-05-26 2018-12-07 中国科学院深圳先进技术研究院 一种猴类脑区的病毒注射方法及应用
CA3065946A1 (en) 2017-06-05 2018-12-13 Research Institute At Nationwide Children's Hospital Enhanced modified viral capsid proteins
CN111565834B (zh) 2017-10-20 2022-08-26 特韦斯特生物科学公司 用于多核苷酸合成的加热的纳米孔
CA3100739A1 (en) 2018-05-18 2019-11-21 Twist Bioscience Corporation Polynucleotides, reagents, and methods for nucleic acid hybridization
AU2019293286A1 (en) 2018-06-28 2021-01-07 Crispr Therapeutics Ag Compositions and methods for genomic editing by insertion of donor polynucleotides
WO2020139871A1 (en) 2018-12-26 2020-07-02 Twist Bioscience Corporation Highly accurate de novo polynucleotide synthesis
JP2022522668A (ja) 2019-02-26 2022-04-20 ツイスト バイオサイエンス コーポレーション 抗体を最適化するための変異体核酸ライブラリ
CN113766930B (zh) 2019-02-26 2025-07-22 特韦斯特生物科学公司 Glp1受体的变异核酸文库
US20210047649A1 (en) 2019-05-08 2021-02-18 Vertex Pharmaceuticals Incorporated Crispr/cas all-in-two vector systems for treatment of dmd
EP3983542A2 (en) 2019-06-17 2022-04-20 CRISPR Therapeutics AG Methods and compositions for improved homology directed repair
US11155835B2 (en) * 2019-08-19 2021-10-26 The Catholic University Of America Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells
EP4034566A4 (en) 2019-09-23 2024-01-24 Twist Bioscience Corporation VARIANT NUCLEIC ACID BANKS FOR CRTH2
JP2022548783A (ja) 2019-09-23 2022-11-21 ツイスト バイオサイエンス コーポレーション 単一ドメイン抗体のバリアント核酸ライブラリー
WO2021140615A1 (ja) * 2020-01-09 2021-07-15 哲朗 近藤 新規組換えバクテリオファージ

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1972710A (zh) * 2003-12-17 2007-05-30 美国天主教大学 包含噬菌体纳米颗粒的方法和组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736388A (en) 1994-12-30 1998-04-07 Chada; Sunil Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells
CA2585267A1 (en) * 2004-10-29 2007-02-08 University Of Rochester Modified bacteriophage vectors and uses thereof
MX2009009213A (es) 2007-03-01 2010-03-15 Univ America Catholic Bacteriofago t4 unido a un substrato.
US9217145B2 (en) * 2007-05-15 2015-12-22 Wisconsin Alumni Research Foundation T7 phage peptide display system and uses thereof
JP2010529862A (ja) * 2007-06-16 2010-09-02 スカラブ ゲノミクス， エルエルシー 核酸パッケージングシステム

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1972710A (zh) * 2003-12-17 2007-05-30 美国天主教大学 包含噬菌体纳米颗粒的方法和组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Mapping of functional sites on the primary structure of the tail lysozyme of bacteriophage T4 by mutational analysis;Shigeki Takeda et al;《Biochimica et Biophysica Acta》;19981231;第1384卷;摘要，表1-表3，第249页右栏第2段 *
The N-terminal ATPase Site in the Large Terminase Protein gp17 is Critically Required for DNA Packaging in Bacteriophage T4;Venigalla B. Rao et al;《J. Mol. Biol.》;20011231;第314卷;摘要第1-8,14-16行，第401页左栏第1行至右栏第1行，第401页右栏第2段第7行至402页左栏第2行，第402页第4段 *

Also Published As

Publication number Publication date
WO2011125054A4 (en) 2012-06-28
EP2542681B1 (en) 2019-02-27
US20130196416A1 (en) 2013-08-01
US9523101B2 (en) 2016-12-20
JP5863766B2 (ja) 2016-02-17
JP6127124B2 (ja) 2017-05-10
US20140335158A1 (en) 2014-11-13
CN103003431B (zh) 2014-11-26
US8802418B2 (en) 2014-08-12
CN103003431A (zh) 2013-03-27
CN103725703A (zh) 2014-04-16
WO2011125054A3 (en) 2012-05-10
US20110250263A1 (en) 2011-10-13
JP2013526850A (ja) 2013-06-27
JP2016093183A (ja) 2016-05-26
EP2703491B1 (en) 2017-03-08
EP2542681A4 (en) 2013-10-16
EP2703491A1 (en) 2014-03-05
US9365867B2 (en) 2016-06-14
EP2542681A2 (en) 2013-01-09
WO2011125054A2 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
CN103725703B (zh) 用于制备包装机器的方法以及包装机器
US9163262B2 (en) In vitro and in vivo delivery of genes and proteins using the bacteriophage T4 DNA packaging machine
Fokine et al. Molecular architecture of tailed double-stranded DNA phages
Black et al. Structure, assembly, and DNA packaging of the bacteriophage T4 head
Dong et al. Engineering T4 bacteriophage for in vivo display by type V CRISPR-cas genome editing
Janczuk et al. Bacteriophages in electrochemistry: A review
CN116323944B (zh) 用于人类基因组重塑的基于噬菌体的人工病毒设计
Martino et al. Single-point mutations in Qβ virus-like particles change binding to cells
US10562938B2 (en) Theragnostic particles
Hayes et al. Dual expression system for assembling phage lambda display particle (LDP) vaccine to porcine Circovirus 2 (PCV2)
JP7320883B2 (ja) 遺伝子およびタンパク質の大きな運送物をヒト細胞に送達するための原核生物－真核生物ハイブリッドウイルスベクター
JP2022549257A (ja) ファージｔ５由来ナノ粒子の作製及び機能化並びに治療用途
Wenzel Protein interactions between the bacteriophage T4 tail tip and the inner membrane of Escherichia coli
JP2007089440A (ja) 細胞膜透過ペプチドを提示したナノ粒子による細胞への物質導入
Kurochkina et al. Characterization of tail sheath protein of giant bacteriophage φKZ Pseudomonas aeruginosa
Asija Protein Joinery Using Molecular Cooperation: An Analysis of the Capsid Stabilizing Interactions in Bacteriophage P22
Lambert et al. Phage DNA transfer into liposomes
Schwarz Biomimetic structural engineering of P22 virus-like particles for catalysis and immune modulation
Xiao Molecular mechanism of connector-RNA interaction of bacteriophage phi29 DNA packaging motor and applications of motor components in nanotechnology
Arisaka Stoichiometry of protein interactions in bacteriophage tail assembly

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant